Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2μm filtered concentrated solution in 20mM Tris-HCl, pH8.6, 150mM NaCl.
Endotoxin
Less than 0.1EU/μg of rHuIGF-BP7 as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Cytokine
Background
IGF-BP7, also named IBP-7, Mac25 and IGFBPrP1, is belonging to the superfamily of insulin-like growth factor (IGF) binding proteins and is encoded by the igfbp7 gene in human. It is expressed in a wide range of normal human tissues and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin. IGF-BP7 includes conserved cysteine residues. IGF-BP7 modulates the biological activities of IGF proteins. It also suppresses growth and colony formation of prostate and breast cancer cell lines. Above all, IGF-BP7 is a very important factor in skeletal myogenesis. Human IGF-BP7 cDNA encodes 282 amino acid (a.a.) residue precursor protein with a putative 26a.a. signal peptide. Human and murine IGF-BP7 share 94%a.a. sequence identity.